Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $90.69, which is a 234.53% upside from current levels. In a report released today, BTIG also ...

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed yesterday at $27.09. Confident Inv ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...

For the various different available expirations for SOFI options, VKTX options, or TPR options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » ...

Below is a chart showing VKTX's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for W options, PENN options, or ...

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $26.01, indicating a -1.03% shift from the previous trading day.

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.

In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 1.03% at $26.01. The stock trailed the S&P 500, which registered a daily loss of 0.22%. Elsewhere, the Dow saw an upswing of 0.08 ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...